Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15704MR)

This product GTTS-WQ15704MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Macular edema following Central Retinal Vein Occlusion (CRVO), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15704MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8817MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ7043MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ6631MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ1491MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ3174MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ4083MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ12537MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ11592MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MGAH-22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW